I 医药行业下半年预测及上半年情况分析

Size: px

Start display at page:

Download "I 医药行业下半年预测及上半年情况分析"

侗夜郎
7 years ago
Views:

1 WTO 1 FAX

2 I II III IV V VI FAX

3 FAX

4 I FAX

5 GMP 3 FAX

6 FAX

7 FAX

8 FAX

9 FAX

10 FAX

11 FAX

12 FAX

13 FAX

14 FAX

15 FAX

16 GMP GMP GMP II 14 FAX

17 me--too 15 FAX

18 FDA FAX

19 FDA 6APA 7ADCA 7ACA VC VE VB1 VB6 VH VD FAX

20 18 FAX

21 III FAX

22 FAX

23 10 50 ( ) G V APA ACA ADCA C FAX

24 FAX

25 VA VB VB VC VE FAX

26 V FAX

27 FAX

28 TMP FAX

29 ST SD SM VC VC FAX

30 V B 1 V B ± FAX

31 (1 ) NaCl (8 ) VE FAX

32 VA D VC VB (10 ) VB 6 VB FAX

33 6APA VC VE 4302 VA VB VB VB FAX

34 1620 VB VC VE 6685 SM SD ( ) ± FAX

35 FAX

36 FAX

37 APA ACA 7ADCA FAX

38 V V V 6APA 7ACA 7ADCA FAX

39 ( ) ( ) ( ) FAX

40 ( ) ( ) FAX

41 / / ( ) GDP FAX

42 ,, HPDIS ( ) 1. 1, ( ) ( ) 40 FAX

43 WTO : l l -1.0l FAX

44 l FAX

45 l l ( ) ( ) ( ) ( ) l ( 7.4 ) FAX

46 2. ( ) 40 ( ) ( ) l l l l FAX

47 2 ( ) l l S l ( ) l l l ( ) l FAX

48 5 ( ) ( ) FAX

49 ! IV /6 1/ FAX

50 FAX

51 TEL FAX DNA ( 30 ) DNA 30

52 TEL FAX

53 TEL FAX DNA

54 V FAX

55 l , FAX

56 FAX

57 FAX

58 TEL FAX A * * A *

59 TEL FAX A * * A * A * *

60 TEL FAX * * * * * A *

61 FAX

62 A ST ST ST ST FAX

63 FAX

64 FAX

65 A FAX

66 ST ST ST ST ST FAX

67 , , 25.5, WTO 3 65 FAX

68 ,, ,, FAX

69 FAX

70 GMP,, Cefuroxim e Axetil Glaxo (1998) Insulin Eli Lilly (1999) Estradiol Cibageigy (1993) Nabumeto ne Smith kline beecham (1993) FAX

71 55 Cromoglici c acid Fisons (1993) Terazosin, Hytrin Abbott 5.82 (1999) Zofran Glaxo wellcom e 6.74 (2000) Glucophag e Squibb (1999) Eli 59 Prozac Lilly (2000) Prilosec,lo sec Astra zeneca (2000) Zestril,prin ivil Merck sharp& pohme (1996) Axid,nizati dine Eli Lilly 5.50 (2000) Relafen,na bumetone Smith klin beecham (1999) Biaxin,clar ithromycin Abbott (2000) Cipro,cipr ofloxacin Bayer,Mi les pharm (2000) FAX

72 66 Vasotec Merck (1999) Diflucan Pifzer (2000) Buspar Squibb 6.05 (1999) Zithromax Pfizer (1999) Zocor,simv astatin Merck (2001) Cefprozil,c efzil Squibb (1999) Enrofloxac in 3.00 Bayer (2000) Vovladex Warner 5.60 (2000) Primaxin Merck 5.50 (2000) b LntronA Scherigplough (2000) Ortho- Novum Orthopha rmaceuti (2000) FAX

73 cal 77 Engerix-B Smith kline beecham (2000) Zolof Pfizer (2000) Recefin Roche (2000) Zoladex,go serelin Zeneca (2000) Imitrex Cerenex, Glaxo (2000) Norvasc Pfizer (2000) Gabapenti n Warnera mbert 9.23 (1999) Risperidon e Janssen (2000) Metoprolol fumarate Geigy pherm 5.21 (1999) Qunapril,A ccupril Wellcom e 5.14 (1999) Amlodipin e,norvase Pfizer (1999) Norfloxaci n,noroxin Merck sharp &Dohme FAX

74 89 Somatren, protropin Genentec h Diltiazem HCL,Cardi zen Merrell Dow 5.22 (1999) Zidovudin e,retrovir Burrough s Wellcom e 7.36 (1999) Betametha sone dipropiona te Schering Pergolid mesylate Eli Lilly Granisetro n,dytril 3.00 SB (2000) Paroxetine, paxil SB (2000) Pamidrona te disodium Novartis 5.88 (1999) 2005 Terbinafin e 97 HCL,Lami sil Novartis 7.01 (1999) Carboplati n,paraplati n Bristol- Myers Squibb 7.96 (2000) Zolpiderm, Ambien Pharmaci a 5.72 (1999) Tramadol Janssen FAX

75 Hcl (1999) Cisaprid,pr opulsid Janssen (1999) Fluticason, flonase Glaxo Wellcom e (1999) Cetirazine, zrytec Pfizer (1999) Divalproex,depakote Abbott (1999) tamotidine, pepcid Merck 9.10 (1999) Lansopraz, prevacid Tap Holdings (1999) Taxol,pacli taxel BMS (1999) Orlistat,X Enical Hoffman -La Roche 4.99 (1999) Avonex, Biogen (1999) Genotropin Genentec /pharmac ia (2000) Epogen/oc rit Amgen (2000) FAX

76 ( ) FAX

77 TEL FAX VI 512 A B C D E E D C B A E D C B A

78 A 0 B C D E A B -20 C D E 76 FAX

79 A 60 B 55 C D E A 3 B C 2 D E 77 FAX

I 我国输液发展现状及对策

I 我国输液发展现状及对策 2002 2 2002 8 WWW.CEI.GOV.CN 2 10 111 2001 TEL 01068558557 1 FAX 01068558370 ---- I... 2... 2,... 3... 4... 4... 5... 6 II... 7... 7... 9... 9... 11 28... 12 37... 14... 16... 19 2002... 19 2002... 23